Actively Recruiting
Transcatheter Aortic Valve Replacement for Pure Severe Aortic Valve Regurgitation
Led by Xijing Hospital · Updated on 2024-04-24
500
Participants Needed
1
Research Sites
830 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this multicenter, prospective and observational registry is to evaluate the safety and efficacy of TAVR for treatment of pure severe aortic valve regurgitation. Baseline characteristics, procedural and clinical data will be collected
CONDITIONS
Official Title
Transcatheter Aortic Valve Replacement for Pure Severe Aortic Valve Regurgitation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with severe aortic valve regurgitation and evaluated by the Heart team as eligible for TAVR therapy
- Patients who understand the study purpose, agree to participate, and sign informed consent
You will not qualify if you...
- Patients unable to provide informed consent
- Patients treated with TAVR for aortic stenosis
- Patients currently participating in other clinical trials
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Xijing Hospital
Xi'an, Shannxi, China, 710032
Actively Recruiting
Research Team
R
Rutao Wang, M.D, Ph.D
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here